The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into the active metabolites 4-hydroxytamoxifen and, in particular, endoxifen to achieve its therapeutic effect. As several women treated with tamoxifen may experience depressive symptoms or may have a previous or actual major depressive episode with ongoing antidepressant treatment or need for a new-onset therapy, the coprescription of an antidepressant drug may be particularly problematic as several antidepressants are potent CYP2D6-inhibiting drugs. We herein report a case of a patient with major depression and concurrent tamoxifen therapy successfully treated with agomelatine monotherapy.
Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report / De Berardis, Domenico; Brucchi, Maurizio; Serroni, Nicola; Valchera, Alessandro; Fornaro, Michele; Mazza, Monica; Martinotti, Giovanni; Di Giannantonio, Massimo. - In: CLINICAL NEUROPHARMACOLOGY. - ISSN 1537-162X. - 37:1(2014), p. 31-3. [10.1097/WNF.0000000000000009]
Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report
Fornaro, Michele;
2014
Abstract
The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into the active metabolites 4-hydroxytamoxifen and, in particular, endoxifen to achieve its therapeutic effect. As several women treated with tamoxifen may experience depressive symptoms or may have a previous or actual major depressive episode with ongoing antidepressant treatment or need for a new-onset therapy, the coprescription of an antidepressant drug may be particularly problematic as several antidepressants are potent CYP2D6-inhibiting drugs. We herein report a case of a patient with major depression and concurrent tamoxifen therapy successfully treated with agomelatine monotherapy.File | Dimensione | Formato | |
---|---|---|---|
PRE-PRESS.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
Accesso privato/ristretto
Dimensione
74.81 kB
Formato
Adobe PDF
|
74.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.